Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.5425
-0.0342-5.93%
Pre-market: 0.57450.0320+5.90%08:00 EDT
Volume:2.05M
Turnover:1.13M
Market Cap:158.42M
PE:-2.72
High:0.5780
Open:0.5740
Low:0.5421
Close:0.5767
Loading ...

Ocugen Receives Approval to Begin Dosing in Phase 2 Trial of CU410ST to Treat Genetic Eye Disease

MT Newswires Live
·
22 Oct 2024

Ocugen announces DSMB for OCU410ST trial approved enrollment for second phase

TIPRANKS
·
22 Oct 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of Ocu410st Gardian Clinical Trial for Stargardt Disease

THOMSON REUTERS
·
22 Oct 2024

Ocugen Inc - No Serious Adverse Events Reported for Ocu410st

THOMSON REUTERS
·
22 Oct 2024

Ocugen Inc - High Dose of Ocu410st Determined as Maximum Tolerated Dose

THOMSON REUTERS
·
22 Oct 2024

Ocugen Inc - Gardian Clinical Trial Conducted at 6 Retinal Surgery Centers in U.S.

THOMSON REUTERS
·
22 Oct 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

GlobeNewswire
·
22 Oct 2024

Ocugen Inc. Stock Outperforms Market Despite Losses On The Day

Dow Jones
·
22 Oct 2024

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
19 Oct 2024

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

GlobeNewswire
·
17 Oct 2024

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
17 Oct 2024

Ocugen Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $4

THOMSON REUTERS
·
15 Oct 2024

Ocugen initiated with a Buy at Maxim

TIPRANKS
·
15 Oct 2024

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
15 Oct 2024

Ocugen Inc. Stock Rises Friday, Outperforms Market

Dow Jones
·
12 Oct 2024

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

GlobeNewswire
·
10 Oct 2024